Effectiveness and Safety of Pemetrexed Versus Docetaxel as a Treatment for Advanced Non-small Cell Lung Cancer: a Systematic Review and Meta-analysis |
Di, Bao-Shan
(The First Clinical Medical School of Lanzhou University)
Wei, Kong-Ping (Department of Pediatrics, the Second Hospital of Lanzhou University) Tian, Jin-Hui (Evidence Based Medicine Center of Lanzhou University) Xiao, Xiao-Juan (Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University) Li, Yan (Department of Computer Science, Gansu Institute of Political Science and Law) Zhang, Xu-Hui (Department of Geratology, The Affiliated Hospital of Gansu College of Traditional Chinese Medicine Lanzhou) Yu, Qin (The First Clinical Medical School of Lanzhou University) Yang, Ke-Hu (Evidence Based Medicine Center of Lanzhou University) Ge, Long (Evidence Based Medicine Center of Lanzhou University) Huang, Wen-Hui (Department of Nephrology, Gansu Provincial Hospital) Zhang, Fang-Wa (Evidence Based Medicine Center of Lanzhou University) |
1 | Rodrigues-Pereira J, Kim J H, Magallanes M, et al (2011). A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol, 6, 1907-14. DOI |
2 | Sun Y, Wu YL, Zhou CC, et al (2013). Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study. Lung Cancer, 79, 143-50. DOI ScienceOn |
3 | Zhang X, Qin Y, Li H, et al (2011). Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and metaanalysis. Asian Pac J Cancer Prev, 12, 2857-63. |
4 | Klionsky DJ, Abdalla FC, Abeliovich H, et al (2012). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 8, 445-544. DOI |
5 | Li R, Sun L, Wang J, et al (2012). Pemetrexed versus docetaxel in second line non-small-cell lung cancer: Results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. Pulm Pharmacol Ther, 25, 364-70. DOI ScienceOn |
6 | Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51. DOI ScienceOn |
7 | Shi X, Yu XM, Zhang YP, et al (2013). Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi, 35, 221-4. |
8 | Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA:Cancer J Clin, 62, 10-29. DOI ScienceOn |
9 | Socinski MA, Raju RN, Stinchcombe T, et al (2010). Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV nonsmall cell lung cancer. J Thorac Oncol, 5, 1963-69. DOI ScienceOn |
10 | Chen M, Zhou CC, Zhang J (2008) Comparison of the curative effects of Pemetrexed and Docetaxel in patients with nonsmall-cell lung cancer. J Tong Ji University, 29, 54-7. |
11 | Alimujiang S, Zhang T, Han Z G, et al (2013). Epidermal growth factor receptor tyrosine kinase inhibitor versus placebo as maintenance therapy for advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev, 14, 2413-19. 과학기술학회마을 DOI ScienceOn |
12 | Baldwin CM, Perry CM (2009) Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer. Drugs, 69, 2279-302. DOI ScienceOn |
13 | Calvert H (1999). An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol, 26, 3-10. |
14 | Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. DOI ScienceOn |
15 | Fathi AT, Brahmer JR (2008). Chemotherapy for advanced stage non-small cell lung cancer. Semin Thorac Cardiovasc Surg, 20, 210-6. DOI ScienceOn |
16 | Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. DOI ScienceOn |
17 | Guo RR, Cu FH, Sun HY (2008). Docetaxel as a Second-line Treatment for Patients with Advanced Non Small Cell Lung Cancer: A Systematic Review. Chinese J Evidence-based Med, 8, 861-68. |
18 | Higgins J, Green S (2005). Cochrane handbook for systematic reviews of interventions 4.2. 5 [J]. The Cochrane Library (3). |
19 | Adjei AA (2004) Pharmacology and mechanism of action of pemetrexed. Clinical Lung Cancer, 5, 51-5. DOI |
20 | Qi WX, Shen Z, Lin F, et al (2012). Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 5177-82. 과학기술학회마을 DOI ScienceOn |